1. <li id="3ilqu"></li>
    <th id="3ilqu"><legend id="3ilqu"></legend></th>
    1. <th id="3ilqu"><legend id="3ilqu"><kbd id="3ilqu"></kbd></legend></th>

        <button id="3ilqu"></button><li id="3ilqu"></li>
      1. <i id="3ilqu"><label id="3ilqu"></label></i>

        <th id="3ilqu"><legend id="3ilqu"><kbd id="3ilqu"></kbd></legend></th>
        中文/ 繁体/ English

        1. The immunogenicity and safety of vaccination with purified vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen

        来源:本站        日期:2015-07-14

        广州CDC临床研究显示,成大速达5针法和“2-1-1”程序均有良好的免疫原性和安全性?!?-1-1”程序比5针法早期抗体产生更快,滴度更高。


        Hum Vaccin. 2011 Feb;7(2):220-4. Epub 2011 Feb 1.

        Liu H1Huang GTang QLi JCao SFu CCao QLiu BPan HWang M.

        ·         1 Guangzhou Center for Disease Control and Prevention, Guangzhou, Guangdong Province, China.


        Abstract

        BACKGROUND:

        In China, rabies vaccine is only permitted to use under the Essen 5-dose regimen for the rabies post-exposure prophylaxis (PEP). However, Purified chick embryo cell vaccine made in India (Rabipur) has been approved in use under 2-1-1 immune program in 2010. Our objective is to confirm the immunogenicity and safety of PVRV manufactured in China (SPEEDA) under 2-1-1 program, compared with Rabipur and with the Essen 5-dose regimen.

        METHODS:

        A total of 112 subjects were divided into three groups: 50 subjects in test group A, 32 subjects in control group B and 30 subjects in control group C. "Zagreb" 2-1-1 program was chosen for group A and B using SPEEDA and Rabipur, "Essen" 5-dose regimen was adopted for group C using SPEEDA, thus to observe the general and local reactions within 72 h post vaccination. Serum samples were also collected at D0, D7, D14 and D45 to determine the rabies serum neutralizing antibody by rapid fluorescent focus inhibition test (RFFIT).

        RESULTS:

        All groups showed similar immunogenicity. The neutralizing antibody titers at D14 and D45 of all subjects showed more than 0.5 IU/ml. No moderate and severe adverse effects were observed, though mild adverse reactions may occur.

        CONCLUSIONS:

        PVRV (SPEEDA), under 2-1-1 regimen, is equally safe and immunogenic as the PCECV (Rabipur) for post-exposure prophylaxis vaccination.


        /upload/file/20150713/20150713174249_6357.pdf

        成年美女黄网站色大全视频,日韩欧美成人免费观看,美女流白浆视频在线网站